Details of the Drug

General Information of Drug (ID: DMXLYQF)

Drug Name
Belatacept
Synonyms Nulojix (TN); Belatacept (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Kidney transplant rejection NE84 Approved [1]
Heart transplant rejection NE84 NDA filed [1]
Affected Organisms
Humans and other mammals
ATC Code
L04AA28: Belatacept
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Sequence
MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTF
LDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPC
PDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 9.8 days [2]
Metabolism
The drug is metabolized via proteolytic enzymes []
Vd
The volume of distribution (Vd) of drug is 0.11 L/kg []
Cross-matching ID
UNII
E3B2GI648A
DrugBank ID
DB06681
TTD ID
D0N4HB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell-specific surface glycoprotein CD28 (CD28) TTQ13FT CD28_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Belatacept (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Belatacept and Teriflunomide. Hyper-lipoproteinaemia [5C80] [4]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Belatacept and Tecfidera. Multiple sclerosis [8A40] [5]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Belatacept and Siponimod. Multiple sclerosis [8A40] [6]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Belatacept and Fingolimod. Multiple sclerosis [8A40] [7]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Belatacept and Ocrelizumab. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Belatacept and Ozanimod. Multiple sclerosis [8A40] [9]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Belatacept when combined with Anthrax vaccine. Sepsis [1G40-1G41] [10]
⏷ Show the Full List of 7 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6892).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
4 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
5 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
8 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]